PolyHeme Phase III Clinical Trial
GPTKB entity
Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:conditionStudied |
traumatic hemorrhagic shock
|
| gptkbp:controls |
standard blood transfusion
|
| gptkbp:endDate |
2006
|
| gptkbp:enrollment |
720
|
| gptkbp:hasEthics |
conducted under emergency research consent waiver
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:period |
Phase III
|
| gptkbp:recognizedBy |
NCT00076648
|
| gptkbp:result |
no significant difference in survival
survival at 30 days |
| gptkbp:resultPublication |
Journal of the American College of Surgeons, 2009
|
| gptkbp:sponsor |
gptkb:Northfield_Laboratories
|
| gptkbp:startDate |
2003
|
| gptkbp:studiedDrug |
gptkb:PolyHeme
|
| gptkbp:studyType |
gptkb:clinical_trial
|
| gptkbp:bfsParent |
gptkb:Artificial_Blood
|
| gptkbp:bfsLayer |
8
|
| https://www.w3.org/2000/01/rdf-schema#label |
PolyHeme Phase III Clinical Trial
|